Abstract Cancer risks and medical management of Lynch syndrome (LS) differ from other hereditary or familial clustering of colorectal cancer. Differential diagnosis has improved as a result of the growing clinical and molecular knowledge about LS. Appropriate application of these advances in several scenarios constitutes a decision-making process to further decide germ-line testing with accuracy and effi ciency. However, an only molecular-screening algorithm, with a limited number of steps and choices, may be diffi cult to devise. How, when, where and at what expense to use the different diagnostic tools remain dynamic and changeable under different circumstances. From a clinical point of view, it is advisable to discuss confl icting aspects to guide LS diagnosis.
Introduction
Lynch syndrome (LS) is a hereditary form of colorectal cancer (CRC). Its prevalence is 2-5% of newly diagnosed patients with CRC [1] . LS is an autosomal dominant disorder caused by germ-line mutations in DNA mismatch repair (MMR) genes (MLH1, MSH2, MSH6, PMS2), which lead to a characteristic mutator phenotype: microsatellite instability (MSI) and loss of MMR protein expression. Lifetime cancer risk related to LS is 24-75% for CRC, 27-71% for endometrial adenocarcinoma, 3-13% for ovarian carcinoma, 2-13% for gastric carcinoma, 1-12% for urinary tract cancer, 1-4% for brain gliomas, 2-4% for bile duct/gallbladder/pancreatic cancer and 4-7% for small bowel cancer [1] .
Intensive colonoscopic screening reduces CRC incidence by 63% and improves overall and CRC-related survival [2] . Annual endometrial sampling, beginning between age 30 and 35, is recommended for women with LS. Prophylactic hysterectomy and bilateral salpingo-oophorectomy can be offered as an option for cancer prevention to women aged 35 years or older who do not want to preserve fertility, since it substantially reduces site-specifi c cancer [3] .
About 45% of families with Amsterdam criteria (AC) ( Table 1) have no evidence of a DNA MMR gene muta-tion or defi ciency of DNA MMR in their tumours. These families are designated as familial colorectal cancer type X (FCC-X) [4] . For FCC-X diagnosis, the LS mutator phenotype should be discarded in more than one CRC to exclude phenocopies. FCC-X families show increased incidence mainly for CRC (SIR, 2.3; 95 confi dence interval, 1.7-3.0), but lesser and to an older age than in LS families. Rates of second primary CRC are lower, fewer tumours occur in the proximal colon and extracolonic cancer risks are not elevated. The screening is based on the profi le of cancer in the family and it is less aggressive than that proposed for LS (Table 3) . Then, for FCC-X and other families with clustering of CRC, colonoscopic surveillance is recommended every 3-5 years beginning 5-10 years before the youngest case in the family or at 45 years.
Clinical and molecular diagnostics have evolved in recent years towards better identifi cation of LS and distinction from other CRC clustering. Although controversies may exist, some kind of decision-making process for germline testing in LS is unavoidable. We show important questions to solve at each stage which indicate the diagnostic pathways.
Pre-selection of individuals for LS: population-based approach
Molecular diagnostics of LS can combine several phases. The fi rst stage is identifying who to test for LS [5] . This population-based approach can be attempted at any, well informed, health care level.
Family history, and clinical and pathologic features of the tumours may raise a suspicion that LS is present. Patients should be referred to a genetic counselling (GC) unit when clinical criteria are met. In newly diagnosed CRC from the general population, the revised Bethesda guidelines (rBG) ( Table 2 ) have a 72-100% sensitivity to identify carriers of a deleterious mutation in MMR genes [6, 7] . In addition to the AC, the rBG are recommended for selecting which tumours to study with molecular tests.
However, it has been reported that rBG would lose 28% cases of LS in a cohort of unselected patients with CRC, whereas immunohistochemistry (IHC) and MSI would be highly and equally sensitive to detect LS in this scenario [6, 7] . Some authors promote active, large-scale pre-screening with molecular studies performed on population-based CRC tumours. Nowadays, with shorter and different family structures, it becomes a reasonable option. Cost-saving, ethical and legal aspects must be considered for this purpose. In this sense, IHC advantages and previous genetic counselling may help overcome diffi culties. New and more economical panels of IHC and MSI can also be considered [17, 18, [34] [35] [36] , although more confi rmatory studies would be needed. It should be considered that 5-9% of endometrial cancer patients younger than age 50 years have been found to carry LS-associated mutations (mainly MSH2 mutations) [8] . This prevalence is similar to that reported for patients with one of the rBG criteria (CRC diagnosed before 50 years old) [7] , which argues in favour of testing women with endometrial cancer younger than age 50 years.
Statistical models perform well in the population-based setting. A probability 5% with PREMM1,2 model has shown a 100% sensitivity for the identification of LS cases in a Spanish cohort of unselected patients with CRC [9] . Stage 1 Barnetson model, at a cut-off point of 0.005, equals rBG in accuracy for the prediction of carrier stage among incident cases of CRC diagnosed before the age of 55 years [10] .
In a population-based pre-screening, CRC molecular studies could be an alternative for identifying who to test for LS. Although prospective validation of statistical models is encouraged, they could also be accepted as rBG previously were [11] . Choice could depend on particular experience, logistics and organisation of GC in each region.
Different strategies and criteria (endometrial cancer before 50 years) could be added by active, large-scale, GC programmes, under the assumption of cost-effectiveness (Fig. 1) .
Selection of individuals for LS: risk population approach
rBG and molecular evaluation of CRC (MSI testing and IHC) are highly effective (sensitivity >81%, specificity >98%, positive predictive value (PPV) >27%) to identify MMR gene mutation carriers [7] . Statistical models in conjunction with CRC molecular evaluation yield good prediction accuracy in retrospective analysis [9, 10] . How to effi ciently combine clinical criteria, statistical models and CRC molecular studies requires knowledge, experience and skills in GC and LS diagnostics. This risk population approach must be attempted at GC clinics.
At the GC units, statistical models may help elect individuals and guide the molecular evaluation (i.e., PREMM1,2,6; MMRPro, MMRpredict) [12, 13] . In a Spanish cohort of individuals with germline tests or CRC molecular analysis for LS, PREMM 1,2,6 and MMRPro 5% select less individuals than rBG (72 and 74% vs. 82%) but lose less mutation carriers (6 and 8% vs. 27%) [14] . Furthermore, statistical models provide a LS probability, which constitutes an excellent tool for communicating risks that are easy to understand. Clinical criteria and statistical models should constitute the initial evaluation for deciding molecular diagnostics (Fig. 1 ). Statistical models are also useful to decide how much accuracy must be enhanced in diagnosis. MMRPro extends its clinical application to the post-test setting, since it also predicts mutation probability after having performed CRC molecular studies or germ-line tests, allowing GC even without positive results.
In the most compelling clinical presentation, the yield of direct germline mutational testing is often less than 50%. As mentioned before, CRC molecular studies along with clinical evaluation are more effective. Then, proceeding to CRC molecular tests must be the next stage ( Fig. 1) .
Results of CRC molecular analysis, and of germ-line mutation testing as well, can be complex and the data should be interpreted together by a multidisciplinary team.
CRC molecular approach: IHC
IHC with MLH1/MSH2 has a lower sensitivity than MSI testing in predicting gene mutation, but inclusion of PMS2 and MSH6 results in a predictive value equivalent to that of MSI testing [15] . PMS2 IHC detects 23% of MLH1 mutated tumours lost by MLH1 IHC [16] . MSH6 IHC also predicts mutations not suspected by MSI. Mutations of MLH1 or MSH2 often cause concurrent loss of MLH1/ PMS2 or MSH2/MSH6 proteins respectively, but mutations of PMS2 or MSH6 often cause isolated loss of PMS2 or MSH6 only. Then, some authors have advocated an IHC panel only with PMS2 and MSH6 antibodies [17, 18] , which could be more cost-effective in the pre-screening scenario. In the high-risk setting, more studies with the two antibodies IHC are advisable, and IHC with four antibodies is preferred to gather the maximum amount of information to effi ciently determine further studies for a correct diagnosis. If the two antibodies panel is used, when informative the four antibodies should be completed, otherwise 15% of patients (PMS2 and MSH6 mutation carriers) could follow the wrong initial diagnostic pathway.
Currently GC units are usually placed at tertiary level hospitals. So IHC presents logistic advantages over MSI analysis and is to be considered the fi rst CRC test (Table  4) . Its availability wherever there is a pathology laboratory is important, whereas MSI requires tumour microdissection and a molecular diagnostics laboratory. At hospitals, it is easier to perform IHC just after CRC surgery. This could avoid dealing with samples in the future (which is often diffi cult and must be strictly regulated by law) [19] and tissue preservation problems as well [25, 26] . Tissue sample is important for treatment decisions, since the patient, in the course of his illness, could need studies on the tumor to further determine molecular targeted therapies. Sparing molecular tests and making a correct diagnosis at a lower cost, and using fewer samples and less time is an important issue.
Regarding IHC as the first attempt may have some benefi ts beyond logistics. IHC is less expensive than MSI. If IHC is informative, some cost savings may be realised, given that IHC can detect the gene most likely mutated for which the protein is lost. Interestingly, when MLH1 is defi cient, additional BRAF and methylation studies may diagnose sporadic CRC, discarding LS in an effi cient way. Mutations in MSH6 have been reported to account for up to 13% of families with MMR gene mutations [20] and the functional redundancy between MSH6 and MSH3 may explain why some MSH6 mutations do not result in MSI in the tumour [32, 33] , whereas they could be detected by MSH6 IHC.
IHC also has disadvantages and a well trained pathologist is always required to overcome some diffi culties (Table  4) . IHC (which needs four sections) may not be reliable in small biopsy samples and does not identify carriers of mutation in other genes not tested by IHC (MSH3, PMS1, unidentifi ed genes). The most important limitations of IHC are the false staining patterns, mainly in MLH1.
More than one-third of the mutations in MLH1 are missense mutations that may result in mutant proteins catalytically inactive but antigenically intact [21, 22] . False-normal staining for MLH1can also occur with protein-truncating mutations and large in-frame deletions in MLH1 [21, 23, 24] . A second hit inactivating the normal allele might result in a profi cient but nonfunctional MLH1 protein, explaining why individuals with the same germ-line MLH1 mutation exhibit different MLH1 IHC patterns [24] . In these situations PMS2 protein may be lacking.
MLH1 IHC focal and weak in intensity is usually a problem. Tissue hypoxia and oxidative stress have been demonstrated to impair MMR function in genetically MMR-profi cient tumours and may give this pattern of focal and weak or even absent MLH1 staining [25, 26] . Lack of staining in a small biopsy sample may not be interpreted as loss of protein in the entire tumour. These two situations must be advised by a pathologist with adequate expertise in this fi eld. In general, the presence of some degree of nuclear staining is evidence of retained MMR protein, but with positive internal control this may refl ect certain types of gene mutation [27] , mainly if PMS2 protein is not present. If repeated attempts fail to assess positive internal controls, the result must be considered inconclusive.
Focal staining with unimpaired intensity and positive internal control is frequently seen with MSH6 IHC, sometimes constituting a percentage of the tumour. If accompanied by MLH1 defi ciency, it could be explained by a secondary MSH6 mutation in subclonal populations of a MSI tumour, giving an aberrant IHC pattern. But we have to bear in mind that some MSH6 missense mutations (as frequent as MSH6 truncating mutations) increasing the risk of cancer may not completely abrogate MSH6 protein, and new MSI panels could detect the impaired DNA MMR system [34] [35] [36] . The different clinical phenotype of LS linked to MSH6 mutations must also be considered, with CRC at an older age, which can co-exist with sporadic CRC with normal IHC, so that the possibility of phenocopy is higher in these families.
CRC molecular approach: MSI analysis
MSI is widely accepted as the main hallmark of CRC related to LS. Some advantages of MSI analysis are obvious (Table 5) : laboratory directors can be profi ciently trained to read MSI results; the MSI unstable pattern can be easily recognised with certainty; laboratory-to-laboratory reproducibility is high; quality controls of MSI testing can be performed; MSI can potentially identify a tumour with defective DNA but intact staining possibly due to non-truncating missense alterations (mainly in MLH1 and MSH6) or mutations in other MMR genes or unknown genes whose proteins are not included in the IHC panel; and with small biopsy samples, MSI analysis can be done in one pathologic section correctly microdissected [28] .
Despite these advantages, logistic limitations for the frontline CRC molecular approach have already been discussed. From a realistic point of view, the fi rst CRC (Table  5) . MSI is seen in 10-15% of sporadic CRC, and MLH1 IHC can better guide subsequent studies for their correct diagnosis. Tumours with germline mutations in MSH6 may tend to show a low level of MSI [29] [30] [31] , which can be explained by the fact that the MSH2/MSH3 dimer is still functioning so that MSI is limited to mononucleotide tandem repeats [32, 33] . These mutations could be detected by MSH6 IHC.
As mentioned before, some MSH6 missense mutations may not present with MSH6 protein loss. The addition of mononucleotide markers to MSI testing, such as BAT-40, reclassifi es some MSI-low tumours as MSI-high tumours [31] . It is supposed that when a suffi cient number of mononucleotide markers are used, more CRC with MSH6 germline mutation will be considered as MSI-high tumours. To improve the accuracy of MSI testing, the 2002 National Cancer Institute workshop recommended a secondary panel of mononucleotide markers [11] . The Promega MSI Analysis System [34] [35] [36] has been developed as a panel with 5 mononucleotide quasi-monomorphic markers, which do not require healthy tissue, resulting in higher specifi city and sensitivity, and reduced cost. CAT25 microsatellite marker, placed in the CASP2 region, is another useful marker for detecting MSH6 germline mutated tumours. The possibility of phenocopy should always be considered in LS related to MSH6 mutations.
IHC is not always conclusive and in that case MSI should be done, because concordance between both tests is not perfect and important diagnostic value may be added. In some instances, it is preferable to consider the complementary test to avoid pitfalls in the trascendental question of ensuring or excluding LS diagnosis.
Molecular diagnostics pathways: MMR protein-profi cient tumours
IHC analysis data are often the fi rst available results and they can trace diagnostic tracks to follow with effi ciency and accuracy.
Once IHC on the CRC reveals correct expression of MLH1, MSH2, MSH6 and PMS2 proteins, only an estimate of low mutation probability in well selected families could avoid further studies and rule out LS.
However, in general, complementary molecular MSI testing is usually advised. If the tumour results show stability or low MSI, the presence of LS is not likely. The possibility of phenocopy must always be excluded. This may require molecular analysis of more than one CRC in AC families. With no phenocopies or LS tumour phenotype after IHC and MSI testing, FCC-X diagnosis can be made in AC families [4] .
On the other hand, it has been clearly stated that IHC and MSI analysis can both miss tumours with MSH6 germline mutations [29] . It is not a general rule but, in patients with normal IHC and low MSI, when AC criteria are met or statistical models raise a high LS suspicion (e.g., MMRPro applied after MSI testing), proceeding to MSH6 germ-line mutation testing can be considered in exceptional cases. At this stage, there is controversy surrounding progression to MLH1 germ-line mutation testing for the rare cases of second hits restoring antigen expression of a nonfunctional MLH1 protein, also with PMS2 presence [24] .
In MMR protein-proficient tumours with high MSI, MMR genes germ-line mutation testing must be performed, paying special attention to possible MLH1 or MSH6 mutations. If a pathogenic mutation is encountered, a diagnosis of LS is made. If no mutations are seen, LS cannot be excluded with a probability of mutations in other MMR or unknown genes that MMRPro applied after MSI could estimate (Fig. 2) . Clinical judgment must guide the screening protocol for these families, which should be based on the familial cancer profi le and the probability of mutation.
Molecular diagnostics pathways: MLH1 protein-defi cient tumours
As previously mentioned, these tumours are often PMS2 defective and also MSI high.
In AC families or when LS suspicion is high by statistical models, direct MLH1 germ-line mutation testing may be chosen and, if negative, PMS2 mutation testing is more debatable. But, regarding costs and complexity of germ-line testing, given that 10-15% of sporadic CRC are MSI-high, often with MLH1-lacking tumours due to hypermethylation in the MLH1 promoter, studying a single somatic mutation in the BRAF gene is usually the fi rst option to preclude LS.
Somatic V600E BRAF mutation is found in 40% of MSIhigh CRC and in 5% of microsatellite stable CRC [37] [38] [39] . Sixty-eight percent of sporadic CRC harbours the V600E mutation, usually with MLH1 methylation and loss of the MLH1 protein [41] . Most importantly, BRAF mutation has not been detected in LS tumours [40] [41] [42] [43] , whereas it is frequently present in sporadic CRC with MLH1 hypermethylation. So, in MLH1-defi cient tumours, the presence of V600E BRAF mutation excludes LS with nearly 100% specifi city.
In sporadic proximal colon tumours with high MSI and MLH1 methylation, V600E BRAF mutation is encountered in 80% of cases. In a cohort of sporadic CRC, MLH1 hypermethylation has been proven to be more frequent than BRAF mutation [44] . This may mean that some sporadic CRC with MLH1 methylation do not present the V600E mutation. MLH1 promoter hypermethylation is an epigenetic change that alters gene function often without genetic changes at the DNA sequence level, causing the MSI phenotype, but in sporadic CRC [45, 46] . Then, in MLH1 defective tumours without BRAF mutation, the next diagnostic step could be testing somatic hypermethylation in the MLH1 promoter, as a direct test to exclude LS also avoiding germ-line studies.
In general, when somatic BRAF mutation is absent and MLH1 hypermethylation is present in the tumour, sporadic CRC is the most probable diagnosis and no further tests are needed.
However, we advise on two rare phenomena. MLH1 hypermethylation has been seldom described in tumours with well characterised germ-line defects in MMR genes, so that methylation would act as the second hit inactivating the wild-type MLH1 allele in LS tumours [40, 45, 47] . Furthermore, germ-line epimutations in MLH1 and MSH2 have been reported [48] [49] [50] and a prevalence of 0.6% for MLH1 germ-line hypermethylation has been established in selected patients with MLH1-defi cient tumours [51] . A transgenerational epigenetic inheritance has been proposed as a novel pattern for these mutations, which would be considered an early post-zygotic event [48, [52] [53] [54] [55] . Exceptionally, within AC and very highly suspicious families, in the setting of tumours lacking MLH1 protein and BRAF mutation but with somatic MLH1 hypermethylation, proceeding to germ-line mutation testing may be considered in the search of possible germ-line MLH1 epimutations or other MLH1 gene mutations. If these mutations are not encountered, sporadic CRC diagnosis is made.
In tumours lacking MLH1, somatic BRAF mutation and MLH1 hypermethylation, LS is the most likely diagnosis. MLH1 and PMS2 germ-line mutation testing is indicated and, even in the absence of mutation, LS diagnosis would remain (high-MSI confi rmation may be performed to ensure diagnosis and avoid the possibility of a false MLH1 defective IHC) (Fig. 3) .
Molecular diagnostics pathways: MSH2 protein-defi cient tumours
As mentioned before, these tumours are often MSH6 defective. So, molecular change may be considered informative enough to not perform a MSI test initially. Then, proceeding to MSH2 and MSH6 germ-line mutation testing is the fi rst option. If a mutation is found, a diagnosis of LS is made. But if no mutation is encountered, a LS diagnosis may still be pursued in high-risk families determined by clinical criteria (or special clinical phenotype) or statistical models (e.g., MMRPro applied after germ-line study). Then, the EpCAM/TACSTD1 gene may deserve attention.
EpCAM/TACSTD1 gene deletions are a novel event in LS and represent a mechanism for germ-line MSH2 methy- lation, thus resulting in epigenetic silencing of the neighbouring MSH2 gene [56] [57] [58] . It has been found in 19% of LS without germ-line mutations in MLH1 and MSH2 [56] ; in the Netherlands and Germany it appears to be present in at least 2.8-1.1% of the confi rmed LS families and it has been depicted as an American founder mutation [59] . Some authors consider EpCAM deletions as a recurrent cause of LS that should be considered in routine LS diagnostics [56, 60] and this is our opinion also. In a cohort of 194 EpCAM deletion carriers, a 75% (95% CI 65-85) cumulative risk of CRC was found, higher than MSH6 mutation carriers (50%, 95% CI 38-62, p<0.0001); and a 12% (95% CI 0-27) cumulative risk of endometrial carcinoma was established, lower than that of EpCAM-MSH2 combined deletion carriers (50%, 95% CI 20-90, p<0.0001), MSH2 mutation carriers (51%, 95% CI 33-69, p=0.0006) or MSH6 mutation carriers (34%, 95% CI 20-48, p=0.0309) and similar to MLH1 mutation carriers (33%, 95% CI 15-51, p=0.1193) [61] . So, endometrial cancer risk is higher when EpCAM deletion is more extensive, affecting the MSH2 gene.
MSH2 hypermethylation is a tumour characteristic of EpCAM deletion carriers; but it is not a perfect tool to detect these patients, since somatic MSH2 methylation is also a frequent event in other MSH2 germ-line mutations [58] . It could be employed in MSH2-defi cient tumours without MSH2 and MSH6 mutations. IHC has been used to assess EpCAM expression in 26 LS-associated MSH2-lacking tumours and a concomitant EpCAM protein defect was found in four CRC patients [62] . Multiplex ligation probe amplification (MLPA) analysis revealed EpCAM deletion in these four patients, in two patients with EpCAM positive tumours and in none of the patients with other MSH2 germ-line alterations. EpCAM IHC, as an easier and less expensive tool than MSH2 methylation, may be useful (at least in MSH2 defective tumours) to decide EpCAM deletions as the fi rst germ-line analysis when EpCAM protein is lacking.
In MSH2 defective CRC without mutations in MSH2 and MSH6 (and without EpCAM deletions in suspicious families) and proven high MSI, LS is the most probable diagnosis. If the tumour is microsatellite stable or has MSI, LS is not likely; but in high-risk families (e.g., defi ned by MMRPro after MSI and germ-line tests), an undiscovered germ-line mutation in the MSH6 gene could not be excluded (Fig. 4) .
Molecular diagnostics pathways: MSH6 protein-defi cient tumours
We have referred previously to MSH2-and MSH6-deficient tumours. At this point we are focusing on MSH6 only defective tumours. Then, germ-line analysis for MSH6 mutations is the next step, since a low-MSI tumour does not preclude some MSH6 mutations. If the test is positive, a diagnosis of LS is made. If no mutations are found, proceeding to MSI testing is advisable; and in tumours with high MSI, a diagnosis of LS can be made. In microsatellite stable or low-MSI tumours, LS is less likely; but, again, in high-risk families, an undiscovered germ-line mutation in MSH6 gene cannot be excluded (Fig. 4) . We have mentioned before that the presence of some degree of MLH1 nuclear staining is evidence of retained MMR protein but, sometimes, with positive internal control, could reflect certain types of gene mutation [27] , mainly if PMS2 protein is not present. MLH1 methylation is usually, but not always, associated with loss of the MLH1 protein [45] . So, if no PMS2 mutation is encountered and it is a high-MSI tumour, the MLH1 molecular diagnostics pathway may be followed. When low risk is estimated in the family, the BRAF mutation/MLH1 methylation track could be preferred; and when the risk is higher, MLH1 germ-line mutation testing may be attempted fi rst (Fig. 4) .
Molecular diagnostics pathways: PMS2 protein-defi cient tumours

Molecular diagnostics pathways: aberrant IHC staining patterns
Encoded microsatellites, such as mononucleotide repeats of seven or more elements existing in MMR genes [63, 64] , can suffer secondary mutations in LS giving protein loss patterns which differ from the common ones described above. A MLH1-lacking tumour, with MSH6 loss or partially stained, may be due to a secondary MSH6 mutation that occurs in subclones of an established MSI cancer with germ-line MLH1 mutation. This kind of tumour is a rare phenomenon described by some authors [15, 17] and proceeding to germ-line MLH1 mutation testing should be the fi rst attempt.
Germ-line genetic testing
When a CRC does not show the mutator phenotype or is considered as sporadic, phenocopy possibility has to be excluded in some families. As mentioned before, this is advisable in AC families before FCC-X diagnosis. Once a DNA MMR-defective tumour is identifi ed, MMR mutation testing fi nds a pathogenic mutation in more than 60% of patients. A deleterious mutation confi rms LS and allows pre-symptomatic diagnosis. So, any effort in this search is of paramount importance. Interpretation of the results may be diffi cult and requires an expert multidisciplinary team, but some genetic changes remain as variants of uncertain signifi cance.
For germ-line genetic testing, different techniques and strategies can be used, but a discussion of this point is beyond the scope of this review. However, some main ideas have to be present: full gene sequencing and large rearrangement studies (multiplex ligation probe amplifi cation, MLPA) are essential, since the frequency of large rearrangements is 10-20% in LS; well known recurrent or founder mutations should be tested fi rst; a deep evaluation of variants of unknown signifi cance is advisable (segregation, allele frequency in controls, effect on m-RNA for splicing mutations, effect on protein function by bio-informatic analysis, functional assays, amino acid preservation, somatic studies, cell-free assays…); and if no mutations are detected, samples can be saved for future linkage studies (also when LS is not confi rmed).
Conclusions
Increasing knowledge about LS allows enhanced accuracy and effi ciency in diagnosis. This can lead to distinguishing LS from other entities with different cancer risks and clinical management. We have discussed controversies and depicted a decision-making process for the use of diagnostic tools. Showing understandable diagnostic opportunities and diffi culties for each choice, other strategies and proposals may also be valid.
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